SI-BONE, Inc. (SIBN) fair value analysis
Nasdaq · Updated 2026-10-19
SIBN price how computed
Valuation status
No fair-value estimate yetSIBN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for SIBN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $19.68
- Sector
- Healthcare
- 12-month range
- $11.61–$21.40
- Market cap
- $882M
- From 52-week high
- -8.0%
- Shares outstanding
- 44.8M
- Rank in Healthcare by quality score
- #89 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
SI-BONE, Inc. is a medical device company that designs, manufactures, and markets implants and surgical instruments used to treat sacroiliac joint disorders and related conditions of the spine. The company operates primarily in the United States and also serves international markets.
SIBN currently ranks #89 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $882M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $214M
- Net margin
- -6.9%
- EPS (TTM)
- $-0.34
- Gross margin
- 79.5%
- Debt / equity
- 0.04
- Revenue growth (3-yr avg)
- 21.6%
- Shares outstanding
- 44.8M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 60 · neutral
- 50-day average
- $18.97
- 200-day average
- $16.31
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-09
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+40.0%)
2026-03 ▲ beat (+47.4%)
2025-12 ▲ beat (+69.2%)
2025-09 ▲ beat (+31.2%)
2025-06 ▲ beat (+22.2%)
2025-03 ▲ beat (+31.8%)
2024-12 ▲ beat (+18.1%)
2024-09 ▲ beat (+33.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 0 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $25.2
- Target vs last price
- +28.0%
What our data shows for SIBN
- Shares are trading in the upper third of their 12-month price range of $11.61–$21.40.
- The 14-day relative strength index sits at a neutral 60.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- SIBN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the SIBN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — SIBN's derived indicators shifted this week as the 50/200-day trend state moved from mixed to uptrend. This change reflects a positive technical directional signal for the Healthcare sector stock. The valuation verdict remains awaiting full valuation, indicating that comprehensive pricing analysis is still in progress.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' derived indicators for SIBN show a shift in trend positioning this week. The 50/200-day trend state has moved from an uptrend to a mixed state, indicating less directional conviction in the recent price action. The stock's current valuation verdict remains awaiting full valuation.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is SIBN stock undervalued?
TickrTrends has no fair-value estimate for SIBN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is SIBN's TickrTrends verdict?
SIBN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does SIBN compare to other Healthcare stocks?
SIBN ranks #89 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is SIBN overbought or oversold?
SIBN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does SIBN report earnings next?
SIBN's next earnings report is scheduled for 2026-11-09, per the published earnings calendar.
Does SIBN usually beat earnings estimates?
Over its last 8 reported quarters SIBN beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SIBN?
Of 9 analysts covering SIBN, 9 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $25.2 (+28.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.